Cediranib

Jump to: navigation, search
250px
Cediranib
Systematic (IUPAC) name
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-
7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula C25H27FN4O3 
Mol. mass 450.5 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 12 to 35 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

WikiDoc Resources for Cediranib

Articles

Most recent articles on Cediranib

Most cited articles on Cediranib

Review articles on Cediranib

Articles on Cediranib in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cediranib

Images of Cediranib

Photos of Cediranib

Podcasts & MP3s on Cediranib

Videos on Cediranib

Evidence Based Medicine

Cochrane Collaboration on Cediranib

Bandolier on Cediranib

TRIP on Cediranib

Clinical Trials

Ongoing Trials on Cediranib at Clinical Trials.gov

Trial results on Cediranib

Clinical Trials on Cediranib at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cediranib

NICE Guidance on Cediranib

NHS PRODIGY Guidance

FDA on Cediranib

CDC on Cediranib

Books

Books on Cediranib

News

Cediranib in the news

Be alerted to news on Cediranib

News trends on Cediranib

Commentary

Blogs on Cediranib

Definitions

Definitions of Cediranib

Patient Resources / Community

Patient resources on Cediranib

Discussion groups on Cediranib

Patient Handouts on Cediranib

Directions to Hospitals Treating Cediranib

Risk calculators and risk factors for Cediranib

Healthcare Provider Resources

Symptoms of Cediranib

Causes & Risk Factors for Cediranib

Diagnostic studies for Cediranib

Treatment of Cediranib

Continuing Medical Education (CME)

CME Programs on Cediranib

International

Cediranib en Espanol

Cediranib en Francais

Business

Cediranib in the Marketplace

Patents on Cediranib

Experimental / Informatics

List of terms related to Cediranib


Overview

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.

As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.

Further reading

  • Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. PMID 15899831. 

External links


Linked-in.jpg